Neovasc filing for a CE mark approval in Europe
A conversation with Neovasc CEO Fred Colen from the Biotech Showcase 2020 event in San Francisco
News Releases
from 2017
-
November 10, 2017
Neovasc Announces US$65 Million Underwritten Offering of Units Consisting of Common Shares and Warrants To Purchase Common Shares and Concurrent Private Placement of Notes and Warrants
-
November 6, 2017
Neovasc Receives FDA Approval to Initiate Pivotal Reducer Trial
-
November 3, 2017
Neovasc Provides Litigation Update
-
September 12, 2017
Neovasc Provides Tiara™ Clinical Update
-
September 5, 2017
Neovasc’s Reducer System Reviewed in European Heart Journal